ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds

April 29, 2011

ORI Withdraws Requirement For Research Ethics Courses.

February 23, 2001

Cancer Control Planning Conference Delayed To 1977

August 13, 1976

In Brief: Cancer Prevention Fellowship Program Application Sought; Grant Funds Available

March 18, 1994

Exercisers May Have Higher Breast Cancer Survival

October 27, 2006

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013